Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

MDS 2023 | Update on the ADOPTION study: opicapone in Parkinson’s disease

Joaquim Ferreira, MD, PhD, University of Lisbon, Lisbon, Portugal, shares an update on the ADOPTION study (NCT04990284), a randomized, open-label exploratory trial of opicapone in Parkinson’s disease. The trial compared the add-on efficacy of opicapone compared to an extra dose of levodopa in managing motor fluctuations. The aim was to determine whether the opicapone had any benefits in terms of reducing “off time” or periods of impaired mobility. The results of the trial were positive. Comparing opicapone to levodopa, there was a clear benefit of using opicapone, with a reduction in “off time” of around 45 minutes. This expands the potential use of the opicapone to a wider range of Parkinson’s disease patients, enhancing their quality of life. This interview took place at the 2023 International Congress of Parkinson’s Disease and Movement Disorders in Copenhagen, Denmark.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


J.J.F received grants from GlaxoSmithKline, Grunenthal, Fundação MSD (Portugal), TEVA, MSD, Allergan, Novartis, Medtronic and Angelini. Received consultancy and speaker fees and participated in advisory boards for GlaxoSmithKline, Novartis, TEVA, Lundbeck, Solvay, BIAL, Merck-Serono, Merz, Ipsen, Biogen, Acadia, Allergan, Abbvie, Sunovion Pharmaceuticals, Zambon, Affiris, Roche, ONO and SK Chemicals.